CHF10073 + itraconazole

CHF10073 + itraconazole is a drug-drug interaction (DDI) study combination consisting of CHF10073, an investigational inhaled phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, and itraconazole, a potent cytochrome P450 3A4 (CYP3A4) inhibitor. Developed by Chiesi Farmaceutici, CHF10073 is targeted for the treatment of chronic inflammatory airway diseases like chronic obstructive pulmonary disease (COPD). The combination is utilized in Phase 1 clinical trials to characterize the pharmacokinetic profile of CHF10073 when its primary metabolic pathway, mediated by the CYP3A4 enzyme, is inhibited. This assessment is vital for understanding the systemic safety and potential for interactions with other medications in the target patient population.

Other names

CHF 10073 + itraconazole